DBV TECHNOLOGIES S.A. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.69 USD | -0.14% |
|
+4.39% | -27.58% |
| Sales 2024 * | 6.53M 7.02M | Sales 2025 * | 4.89M 5.25M | Capitalization | 117M 125M |
|---|---|---|---|---|---|
| Net income 2024 * | -107M -115M | Net income 2025 * | -74M -79.45M | EV / Sales 2024 * | -8.25 x |
| Net cash position 2024 * | 170M 183M | Net cash position 2025 * | 224M 240M | EV / Sales 2025 * | -21.9 x |
| P/E ratio 2024 * |
-1.58
x | P/E ratio 2025 * |
-2.83
x | Employees | 105 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.11% |
More Fundamentals
* Assessed data
More news
Latest transcript on DBV Technologies S.A.
More press releases
More news
| 1 day | -1.58% | ||
| 1 week | +2.89% | ||
| Current month | -9.21% | ||
| 1 month | -13.35% | ||
| 3 months | -24.99% | ||
| 6 months | -37.03% | ||
| Current year | -28.62% |
1 week
0.65
0.72
1 month
0.650.83
Current year
0.650.99
1 year
0.652.37
3 years
0.656.88
5 years
0.6513.49
10 years
0.6550.57
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel Tassé
CEO | Chief Executive Officer | 64 | 18-11-28 |
| Director of Finance/CFO | 54 | Nov. 05 | |
Pharis Mohideen
CTO | Chief Tech/Sci/R&D Officer | 59 | 19-07-21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Timothy Morris
BRD | Director/Board Member | 61 | 21-02-28 |
Michel de Rosen
CHM | Chairman | 73 | 18-06-21 |
Don Soland
BRD | Director/Board Member | 65 | 15-03-05 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.03% | 0 M€ | 0.00% | - | |
| 0.02% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 0.69 | -0.14% | 38 634 |
| 24-04-24 | 0.691 | +1.62% | 2,576 |
| 24-04-23 | 0.68 | +2.87% | 116,976 |
| 24-04-22 | 0.661 | -3.04% | 43,412 |
| 24-04-19 | 0.6817 | +3.13% | 39,297 |
Delayed Quote Nasdaq, April 25, 2024 at 01:32 pm EDT
More quotes
DBV Technologies specializes in developing solutions for diagnosing and treating food allergies (primarily to peanuts and cow's milk) using a patch (Viaskin®) that administers active ingredients into the top layers of the skin.
Sector
Pharmaceuticals
Calendar
2024-05-01
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
1.212
EUR
Average target price
4.783
EUR
Spread / Average Target
+294.66%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.16% | 70.78B | |
| +10.72% | 9.15B | |
| -17.03% | 4.84B | |
| +37.51% | 4.22B | |
| +3.92% | 3.92B | |
| +18.14% | 2.55B | |
| -24.13% | 2.26B | |
| -29.70% | 2.24B | |
| +9.09% | 1.92B |
- Stock Market
- Equities
- DBV Stock
- DBVT Stock
